Product Information
DOXYCYCLINE MONO 100 MG CAP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.2267 per EA under NDC 68180065208. Its NADAC has been published 603 times since Mar 18, 2015.
FDA first approved this application on Mar 5, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180065208
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXYCYCLINEApproval Type
Generic (ANDA)
FDA Application
ANDA204234FDA Approved
3/5/2014
TE Code
AB
On Market Since
2/20/2015
Pharmacological Classes
Price Statistics
The NADAC for DOXYCYCLINE MONO 100 MG CAP has been published 603 times since Mar 18, 2015, and over the history we have for it it has declined 49.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2267 per EA |
|---|---|
| All-time high | $0.4788 (Jul 15, 2015) |
| All-time low | $0.1624 (Nov 20, 2024) |
| 52-week high | $0.2397 |
| 52-week low | $0.2267 |
| Median price | $0.2643 |
| Average price | $0.2975 |
| Largest weekly change | -35.2% (Nov 20, 2024) |
| Weeks tracked | 603 |
| Tracking since | Mar 18, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the DOXYCYCLINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DOXYCYCLINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXYCYCLINE MONO 100 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DOXYCYCLINE MONO 100 MG CAP, manufactured by Lupin Pharmaceuticals Inc., is $0.2267 per EA (NDC 68180065208), effective Sep 30, 2026.
How has the price of DOXYCYCLINE MONO 100 MG CAP changed over time?
Over the history we have for it, the NADAC for DOXYCYCLINE MONO 100 MG CAP has declined 49.7%. It has been tracked across 603 weekly CMS publications since Mar 18, 2015.
What are the highest and lowest recorded NADAC prices for DOXYCYCLINE MONO 100 MG CAP?
Since Mar 18, 2015, the NADAC for DOXYCYCLINE MONO 100 MG CAP has ranged from a low of $0.1624 (Nov 20, 2024) to a high of $0.4788 (Jul 15, 2015), with a median of $0.2643 per EA.
Are there cheaper alternatives to DOXYCYCLINE MONO 100 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of DOXYCYCLINE MONO 100 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXYCYCLINE MONO 100 MG CAP?
DOXYCYCLINE MONO 100 MG CAP (NDC 68180065208) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.